wxk001

Walter K. Kraft, MD

Contact Dr. Kraft

132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107

(215) 955-9077
(215) 955-5681 fax

Most Recent Peer-reviewed Publications

  1. Medication Complications in Extracorporeal Membrane Oxygenation
  2. The authors reply
  3. Buprenorphine for the treatment of the neonatal abstinence syndrome
  4. Bioactivity of oral linaclotide in human colorectum for cancer chemoprevention
  5. Beta-blocker therapy and impact on outcome after aneurysmal subarachnoid hemorrhage: A cohort study
  6. Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
  7. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers
  8. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome
  9. Pharmacologic and clinical evaluation of posaconazole
  10. Ethanol Pharmacokinetics in Neonates and Infants
  11. Posaconazole tablet pharmacokinetics: Lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects
  12. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
  13. Poor positive predictive value of McConnell's sign on transthoracic echocardiography for the diagnosis of acute pulmonary embolism.
  14. Cardiovascular protection to improve clinical outcomes after subarachnoid hemorrhage: Is there a proven role?
  15. Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract
  16. MK-0448, a specific Kv1.5 inhibitor safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans
  17. Pharmacologic Management of the Opioid Neonatal Abstinence Syndrome
  18. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients
  19. Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis
  20. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease